and performance. Statements that are not historical facts, including statements about Elan or Royalty Pharma or Royalty Pharma's belief and expectation, are forward looking statements. Words such as "believes", "anticipates", "estimates", "expects", "intends", "aims", "potential", "will", "would", "could", "considered", "likely", and variations of these words and similar future or conditional expressions are intended to identify forward looking statements but are not the exclusive means of identifying such statements. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend upon future circumstances that may or may not occur.
Examples of such forward looking statements include (but are not limited to) statements about expected benefits and risks associated with the Further Increased Offer; projections or expectations of profit attributable to shareholders; anticipated provisions or write-downs, economic profit, dividends, capital structure or any other financial items or ratios; statements of plans, objectives or goals of Elan, the Elan Group, RP Management or Royalty Pharma following the Further Increased Offer; statements about the future trends in interest rates, liquidity, foreign exchange rates, stock market levels and demographic trends and any impact that those matters may have on Elan, the Elan Group, RP Management or Royalty Pharma following the Further Increased Offer; statements concerning any future Irish, US or other economic environment or performance; statements about strategic goals, competition, regulation, regulatory approvals, dispositions and consolidation or technological or regulatory developments; and statements of assumptions underlying such statements.
Forward looking statements only speak as of the date on which they are made, and the events discussed in this announcement may not occur. Subject to compliance with applicable law and regulation, Royalty Pharma is not undePage: 1 2 3 4 5 6 7 8 9 10 Related medicine technology :1
. Royalty Pharma Chairman Writes Open Letter to Elan Board2
. Royalty Pharma Announces Offer May Lapse (Be Withdrawn)3
. PDL BioPharma Provides Second Quarter 2013 Royalty Revenue Guidance of $143 Million4
. Royalty Pharma Files Judicial Review Proceedings5
. Royalty Pharma Posts Investor Presentation Summarizing Further Increased Offer For Elan6
. Royalty Pharma Statement Regarding Withdrawal of Elan Lawsuit7
. Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today8
. Royalty Pharma Acceptances Announcement9
. Royalty Pharma Responds To Elans Tysabri Valuation10
. Royalty Pharma Response To Elans "Categorical View On Value"11
. Royalty Pharma Recommends Elan Shareholders vote "NO" on each of the Elan Resolutions at the Elan extraordinary general meeting